The activated AKT can trigger an enhanced glycolytic rate by up-regulating the HK2 activity for carcinogenesis [11,253], and during cancer, PI3K/AKT pathway enhances drug resistance and intercepts the anticancer therapy [254]. This evidence concerns the gene AKT1 and cancer.